← Leaderboards
Daniel N Streblow
Oregon Health And Science University
$31,877,942
Attributed
$37,359,515
Total exposure
26
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.8M · FY2006–25$20M$15M$10M$5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$45,038,353 · 27
By mechanism
U19$19,503,534 · 4
R01$12,796,006 · 5
P01$10,618,158 · 4
R41$599,863 · 2
R21$481,250 · 1
R56$437,500 · 1
Top collaborators
- Antonio E Frias4 shared
- Paul Kievit3 shared
- Charles T Roberts3 shared
- Mark K Slifka3 shared
- Andrew D Yurochko3 shared
- Lark L Coffey1 shared
- Jamie Lo1 shared
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Susan L Orloff$3,100,750
- Mark K Slifka$36,595,057
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionVirusViralCellsPreventProteinsImmuneCytomegalovirusImmune ResponseMediatingAcuteIn VivoMutantResponseReactivation From LatencyBaseInflammatoryVaccinesVirus DiseasesMortalityTransplant RecipientsAntigensChronicExhibits
Grant awards (63)
Vaccine-mediated cross-alphavirus protection for a live attenuated FDA licensed chikungunya virus vaccine$3,248,576
R01 · FY2025 · AI
Human Cytomegalovirus dysregulation of host hematopoietic progenitor cell signaling pathways to modulate latency and reactivation$2,545,712
P01 · FY2025 · AI · contact PI
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease$997,077
R01 · FY2025 · DK
HCMV US28 regulation of host cell signaling in viral latency and reactivation$331,545
P01 · FY2025 · AI · contact PI
Core D: Animal Immunogenicity and Challenge$7,878,231
U19 · FY2024 · AI · contact PI
Human Cytomegalovirus dysregulation of host hematopoietic progenitor cell signaling pathways to modulate latency and reactivation$2,562,331
P01 · FY2024 · AI · contact PI
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease$951,400
R01 · FY2024 · DK
HCMV US28 regulation of host cell signaling in viral latency and reactivation$374,094
P01 · FY2024 · AI · contact PI
International Herpesvirus Workshop$5,000
R13 · FY2024 · AI · contact PI
Human Cytomegalovirus dysregulation of host hematopoietic progenitor cell signaling pathways to modulate latency and reactivation$2,570,795
P01 · FY2023 · AI · contact PI
Project 2 - Novel Therapeutics for Emerging Alphavirus$1,013,095
U19 · FY2023 · AI · contact PI
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease$994,162
R01 · FY2023 · DK
Mechanistic Analysis of Zika Virus Induced Placental Damage During Pregnancy$646,838
R01 · FY2023 · HD · contact PI
HCMV US28 regulation of host cell signaling in viral latency and reactivation$394,269
P01 · FY2023 · AI · contact PI
The Administrative Core$130,739
P01 · FY2023 · AI · contact PI
International Herpesvirus Workshop$7,000
R13 · FY2023 · AI · contact PI
Project 2 - Novel Therapeutics for Emerging Alphavirus$937,499
U19 · FY2022 · AI · contact PI
Mechanistic Analysis of Zika Virus Induced Placental Damage During Pregnancy$624,342
R01 · FY2022 · HD · contact PI
HCMV US28 regulation of host cell signaling in viral latency and reactivation$400,400
P01 · FY2022 · AI · contact PI
Project 2 - Novel Therapeutics for Emerging Alphavirus$1,019,887
U19 · FY2021 · AI · contact PI
Mechanistic Analysis of Zika Virus Induced Placental Damage During Pregnancy$680,493
R01 · FY2021 · HD · contact PI
Optimization of CMV Vector CD8+ T Cell Response Programming by Modification of CMV-Encoded Molecular Mechanisms That Interfere with Unconventional CD8+ T Cell Response Priming$282,216
U19 · FY2021 · AI · contact PI
HCMV US28 regulation of host cell signaling in viral latency and hematopoiesis$254,214
P01 · FY2021 · AI · contact PI
Project 2 - Novel Therapeutics for Emerging Alphavirus$1,020,148
U19 · FY2020 · AI · contact PI
Mechanistic Analysis of Zika Virus Induced Placental Damage During Pregnancy$670,716
R01 · FY2020 · HD · contact PI
Characterizing the Role of CMV Latency in Solid Organ Transplant Rejection$385,000
R01 · FY2020 · AI · contact PI
Optimization of CMV Vector CD8+ T Cell Response Programming by Modification of CMV-Encoded Molecular Mechanisms That Interfere with Unconventional CD8+ T Cell Response Priming$260,769
U19 · FY2020 · AI · contact PI
HCMV US28 regulation of host cell signaling in viral latency and hematopoiesis$256,068
P01 · FY2020 · AI · contact PI
Project 2 - Novel Therapeutics for Emerging Alphavirus$1,056,208
U19 · FY2019 · AI · contact PI
Mechanistic Analysis of Zika Virus Induced Placental Damage During Pregnancy$678,223
R01 · FY2019 · HD · contact PI
Characterizing the Role of CMV Latency in Solid Organ Transplant Rejection$385,000
R01 · FY2019 · AI · contact PI
Biologically Targeted Vaccine for Chikungunya$300,000
R41 · FY2019 · AI · contact PI
Optimization of CMV Vector CD8+ T Cell Response Programming by Modification of CMV-Encoded Molecular Mechanisms That Interfere with Unconventional CD8+ T Cell Response Priming$260,770
U19 · FY2019 · AI · contact PI
HCMV US28 regulation of host cell signaling in viral latency and hematopoiesis$254,200
P01 · FY2019 · AI · contact PI
Novel Therapeutic Strategies Targeting Re-emerging Alphaviruses$974,162
U19 · FY2018 · AI · contact PI
Characterizing the Role of CMV Latency in Solid Organ Transplant Rejection$385,000
R01 · FY2018 · AI · contact PI
Optimization of CMV Vector CD8+ T Cell Response Programming by Modification of CMV-Encoded Molecular Mechanisms That Interfere with Unconventional CD8+ T Cell Response Priming$260,770
U19 · FY2018 · AI · contact PI
HCMV US28 regulation of host cell signaling in viral latency and hematopoiesis$254,200
P01 · FY2018 · AI · contact PI
Novel Therapeutic Strategies Targeting Re-emerging Alphaviruses$1,142,044
U19 · FY2017 · AI · contact PI
Characterizing the Role of CMV Latency in Solid Organ Transplant Rejection$437,500
R01 · FY2017 · AI · contact PI
Optimization of CMV Vector CD8+ T Cell Response Programming by Modification of CMV-Encoded Molecular Mechanisms That Interfere with Unconventional CD8+ T Cell Response Priming$302,159
U19 · FY2017 · AI · contact PI
HCMV US28 regulation of host cell signaling in viral latency and hematopoiesis$289,591
P01 · FY2017 · AI · contact PI
Development of a NHP model for determining the causal relationship between Zika virus infection during pregnancy and fetal microcephaly.$218,750
R21 · FY2017 · HD · contact PI
Novel Therapeutic Strategies Targeting Re-emerging Alphaviruses$993,983
U19 · FY2016 · AI · contact PI
Development of a model for determining the causal relationship between Zika virus infection during pregnancy and fetal microcephaly.$262,500
R21 · FY2016 · HD · contact PI
Characterizing the Role of CMV Latency in Solid Organ Transplant Rejection$210,140
R01 · FY2016 · AI · contact PI
Novel Therapeutic Strategies Targeting Re-emerging Alphaviruses$995,510
U19 · FY2015 · AI · contact PI
Characterizing the Role of CMV Latency in Solid Organ Transplant Rejection$437,500
R56 · FY2015 · AI · contact PI
Novel Therapeutic Strategies Targeting Re-emerging Alphaviruses$1,106,083
U19 · FY2014 · AI · contact PI
CMV Vectored Herpes Simplex Vaccine$299,863
R41 · FY2014 · AI · contact PI
DETERMINATION OF IMMUNE CORRELATES OF PROTECTION FOR CHIKV INFECTIONS$43,647
P51 · FY2011 · RR · contact PI
Mechanisms of CMV latency in accelerated vascular disease$299,068
R01 · FY2010 · HL · contact PI
MECHANISMS OF CMV LATENCY IN ACCELERATED VASCULAR DISEASE$76,080
P51 · FY2010 · RR · contact PI
DETERMINATION OF AGE-RELATED DEFECTS IN CHIKUNGUNYA VIRUS INFECTION$47,603
P51 · FY2010 · RR · contact PI
DETERMINATION OF IMMUNE CORRELATES OF PROTECTION FOR CHIKV INFECTIONS$47,603
P51 · FY2010 · RR · contact PI
Mechanisms of CMV latency in accelerated vascular disease$299,068
R01 · FY2009 · HL · contact PI
New Ops - Determination of Age-Related Defects in Chikungunya Virus Infections$201,738
U54 · FY2009 · AI · contact PI
MECHANISMS OF CMV LATENCY IN ACCELERATED VASCULAR DISEASE$80,343
P51 · FY2009 · RR · contact PI
Mechanisms of CMV latency in accelerated vascular disease$299,068
R01 · FY2008 · HL · contact PI
MECHANISMS OF CMV LATENCY IN ACCELERATED VASCULAR DISEASE$55,512
P51 · FY2008 · RR · contact PI
Mechanisms of CMV latency in accelerated vascular disease$298,502
R01 · FY2007 · HL · contact PI
Mechanisms of CMV latency in accelerated vascular disease$305,833
R01 · FY2006 · HL · contact PI
MECHANISMS OF HCMV-US28 VASCULAR SMOOTH MUSCLE CELL MIGR$37,516
F32 · FY2000 · AI